Workflow
Roche(RHHBY)
icon
Search documents
罗氏警告称:特朗普药价计划将危及500亿美元美国投资
news flash· 2025-05-14 14:43
罗氏控股公司表示,如果美国总统特朗普实施行政命令以降低处方药成本,该公司将需要重新考虑其在 美国的投资计划。这家总部位于瑞士巴塞尔的公司发言人在一份电子邮件声明中表示:"如果拟议的行 政命令生效,罗氏能否为此前宣布的在美国进行的重大投资提供资金将受到质疑。"罗氏公司预计该行 政命令不会对2025年的业务产生影响,但表示它将破坏"美国作为世界领先制药和医疗保健生态系统的 地位,并抑制美国经济增长并导致失业"。 ...
跨国医药研发生产商罗氏:美国总统特朗普关于药品定价的行政命令威胁到罗氏在美国投资500亿美元的计划。
news flash· 2025-05-14 14:03
跨国医药研发生产商罗氏:美国总统特朗普关于药品定价的行政命令威胁到罗氏在美国投资500亿美元 的计划。 ...
RHHBY to Invest $1.25B to Boost Manufacturing Footprint in US
ZACKS· 2025-05-13 13:26
Less than a month after announcing a $50 billion investment in its U.S. operations over the next five years, Swiss pharma giant Roche (RHHBY) has started rolling out the details of its plans.RHHBY unveiled plans to invest over $700 million in a new 700,000-square-foot, state-of-the-art drug manufacturing facility in Holly Springs, NC. Through this new plant, the company intends to support its pipeline of next-generation obesity drugs for Genentech, a member of the Roche group.Roche expects the project to ge ...
罗氏(RHHBY.US)公布“帕妥珠单抗”乳腺癌Ⅲ期研究最新数据
Zhi Tong Cai Jing· 2025-05-13 07:43
Core Insights - Roche (RHHBY.US) announced statistically significant results from the final overall survival (OS) outcomes of the Phase III APHINITY study for patients with HER2-positive early breast cancer, showing a 17% reduction in death risk for those treated with Perjeta, Herceptin, and chemotherapy compared to those receiving Herceptin, chemotherapy, and placebo [1][2] Group 1 - The APHINITY study was a global, Phase III, randomized, double-blind, placebo-controlled trial involving 4,804 operable HER2-positive early breast cancer patients [1] - The primary endpoint of the study was invasive disease-free survival, with secondary endpoints including cardiac and overall safety, overall survival, and health-related quality of life [1] Group 2 - Ten-year survival rates showed that patients receiving the Perjeta regimen had a survival rate of 91.6%, compared to 89.8% for those receiving Herceptin, chemotherapy, and placebo (HR=0.83, 95% CI: 0.69-1.00, p=0.044) [2] - In the pre-specified subgroup of lymph node-positive patients, the death risk was reduced by 21% (HR=0.79, 95% CI: 0.64-0.97) [2] - The previously reported benefits in invasive disease-free survival were maintained (HR=0.79, 95% CI: 0.68-0.92), with no observed benefits in the lymph node-negative subgroup [2] - Safety profiles, including cardiac safety, were consistent with previous studies, with no new or unexpected safety signals identified [2]
Ten-year APHINITY data show Roche's Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer
GlobeNewswire News Room· 2025-05-13 05:00
Core Insights - Roche, in collaboration with Breast International Group (BIG) and other partners, announced significant overall survival results from the phase III APHINITY study for HER2-positive early-stage breast cancer, showing a 17% reduction in the risk of death after ten years for patients treated with a Perjeta-based regimen compared to standard treatment [1][5][6] Group 1: Study Results - The APHINITY study demonstrated that after ten years, 91.6% of patients treated with the Perjeta-based regimen were alive, compared to 89.8% of those receiving standard treatment, with a hazard ratio of 0.83 [6] - A 21% reduction in the risk of death was observed in the subgroup of patients with lymph node-positive disease, with a hazard ratio of 0.79 [6] - The previously reported invasive disease-free survival benefit was maintained, reinforcing earlier analyses [6] Group 2: Treatment Implications - The results validate the Perjeta-based regimen as a standard-of-care treatment for early-stage HER2-positive breast cancer, particularly for high-risk patients [1][3] - Roche's commitment to improving outcomes for HER2-positive breast cancer patients is evident through the development of targeted therapies like Herceptin and Perjeta, which have transformed survival rates [8][9] Group 3: Future Directions - Full results from the APHINITY study will be presented at the 2025 European Society for Medical Oncology Breast Cancer Congress, indicating ongoing research and collaboration in the field [2][5] - The collaborative efforts in the APHINITY study have led to pivotal trials that continue to enhance understanding and treatment of HER2-positive breast cancer [3][4]
Roche announces $550 million investment to expand its Indianapolis diagnostics manufacturing hub
Prnewswire· 2025-05-12 14:30
An investment of up to $550 million by 2030 will establish the Indianapolis site as a hub for manufacturing of Roche's continuous glucose monitoring solution. Expansion will create hundreds of jobs while also enhancing U.S. production capabilities. Increased access to diabetes management tools will help improve health outcomes for patients in the U.S. and globally.INDIANAPOLIS, May 12, 2025 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it plans to invest up to $550 million in its Diagn ...
【欧洲制药股跟随亚洲同行下跌】5月12日讯,在美国总统特朗普表示他将签署一项降低处方药和药品价格的行政命令后,欧洲制药公司的股票周一早盘下跌。在法兰克福上市的诺和诺德、阿斯利康、葛兰素史克和罗氏控股的股价下跌1%至5%不等,表现逊于大盘。此前亚洲制药股也出现下跌。在日本,制药板块下跌超过4%,成为东京证券交易所33个行业分类指数中表现最差的板块。印度制药股也走低。
news flash· 2025-05-12 06:42
金十数据5月12日讯,在美国总统特朗普表示他将签署一项降低处方药和药品价格的行政命令后,欧洲 制药公司的股票周一早盘下跌。在法兰克福上市的诺和诺德、阿斯利康、葛兰素史克和罗氏控股的股价 下跌1%至5%不等,表现逊于大盘。此前亚洲制药股也出现下跌。在日本,制药板块下跌超过4%,成为 东京证券交易所33个行业分类指数中表现最差的板块。印度制药股也走低。 欧洲制药股跟随亚洲同行下跌 ...
罗氏、阿斯利康在中国建厂,跨国药企缘何纷纷“加码”中国市场?
Xin Jing Bao· 2025-05-09 15:40
Core Insights - The recent investments by multinational pharmaceutical companies in China highlight the growing importance of the Chinese market for global players [1][4][5] - The establishment of new production facilities by Roche and AstraZeneca signifies a strategic move to enhance local production capabilities and supply chains [2][3] Investment Projects - Roche has launched a new biopharmaceutical production base in China with a total investment of 2.04 billion yuan, covering approximately 53 acres and 25,000 square meters, aimed at localizing the production of its innovative drug [2] - AstraZeneca's new small molecule drug factory in Wuxi has a total investment of 475 million USD (approximately 3.44 billion yuan) and will enhance production capacity for cardiovascular innovative drugs, expected to be operational by Q4 2028 [2] Market Dynamics - The Chinese pharmaceutical market is experiencing significant growth, driven by an aging population and increasing healthcare demands, with projections indicating that by 2035, nearly 30% of the population will be over 60 years old [4] - In 2024, AstraZeneca reported a revenue of 6.413 billion USD from the Chinese market, accounting for 12% of its global market share, while Novartis achieved 3.9 billion USD from China, reflecting a 21% year-on-year growth [4] Policy Support - The Chinese government is actively promoting foreign investment in the biopharmaceutical sector through policies aimed at facilitating the entry of foreign companies and expediting the approval process for innovative drugs [5] - The rise of Chinese innovative drugs and a favorable research environment are key factors attracting foreign investments, with 31% of new innovative drug candidates introduced by multinational companies in 2024 originating from China [5]
罗氏20亿加码投资上海,布局更多创新药本地化生产
Di Yi Cai Jing Zi Xun· 2025-05-08 09:24
Group 1 - Roche Pharmaceuticals China announced an investment of 2.04 billion RMB to establish a new biopharmaceutical production base in Shanghai, enhancing its supply chain and local production capabilities [1][3] - The new facility will be located in the Zhangjiang Hi-Tech Park, covering approximately 53 acres with a building area of about 25,000 square meters, dedicated to the localized production of the bispecific antibody drug, Rozlytrek® [1][3] - The project is expected to be completed by 2029 and commence production in 2031, marking a significant milestone in Roche's localization efforts in China [1][3] Group 2 - Roche's commitment to the Chinese market remains strong, with the new production base representing a major breakthrough in localizing innovative drug production [3] - The new facility will be Roche's second innovative drug production base in China, working in synergy with the existing base located nearby [3] - Roche aims to further explore localized production of innovative drugs and contribute to the sustainable development of China's biopharmaceutical industry, aligning with the "Healthy China 2030" initiative [3] Group 3 - The Pudong New Area government plans to strengthen the entire chain layout in the biopharmaceutical sector, focusing on both research and manufacturing [4] - The initiative aims to create a world-class biopharmaceutical industry cluster, facilitating the launch of new products and ensuring that innovative drugs benefit the Chinese population [4]
罗氏宣布投资超20亿人民币 在沪新建生物制药生产基地
news flash· 2025-05-08 05:45
Core Insights - Roche Pharmaceuticals announced an investment of 2.04 billion RMB to establish a biopharmaceutical production base in Shanghai [1] - The investment aims to strengthen the company's supply chain and local production capabilities in China, enhancing the complete pharmaceutical value chain [1] - The project is located in Zhangjiang Hi-Tech Park, covering approximately 53 acres with a building area of about 25,000 square meters [1] - The facility is expected to be completed by 2029 and commence production by 2031, focusing on the localized production of the drug Rozlytrek (entrectinib) to meet the demand for innovative therapies in China [1]